Two patents are for HLD-200, a next-generation formulation of methylphenidate; the other patent and the NOA are for HLD-100, a next-generation formulation of amphetamine. Both products are designed
The OptimEyes trial, with FDA guidance, was designed to include a wide variety of DME patients, some of whom had no therapeutic options and were progressing to blindness.
Financial terms of the deal include the payment of $10m as follows: $5m on closing; $2m payable 6 months from closing; and, $3m payable 12 months from closing.
Highlights The agreement includes the creation of an incubator focused on potential treatments for major diseases such as breast cancer and lung fibrosis using the modulation of RHAMM.
ASP0113 is an investigational vaccine candidate under development for the prevention of CMV disease and associated complications in transplant recipients. Vical licensed the vaccine, ASP0113, to Astellas Pharma
Moberg Pharma’s distribution agreement with the Menarini Group – a top 40 global pharmaceutical company – includes Italy, China and eight countries in Southeast Asia. In addition to
Neurodegenerative diseases, such as Alzheimer’s disease (AD), Hutchinson’s Disease, Parkinson’s disease, Kuru, Creutzfeldt-Jakob disease and other spongiform encephalopathies remain major health problems. Currently there are very limited means
NPC-1C targets a unique member of the MUC family that is specific to colorectal cancer with little reactivity to normal cells. Encouraging overall survival (OS) data was observed
"We are very pleased to announce that the FDA has provided these two important designations to our Sanfilippo drug candidates, reflecting their potential to address the significant unmet
SignalRx was awarded a Phase 1 Small Business Technology Transfer Research (STTR) grant from the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH),
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.